Risk Checklist

Start here

What this checklist can—and cannot—do

People researching ibogaine often encounter short safety claims without enough context. The practical question is not whether a single item is checked, but whether a complete picture of health history, current medicines, laboratory findings, and observation needs has been considered together.

For a broader orientation to the subject, the main ibogaine safety overview sets out the evidence, safety, legality, and practical questions this resource covers. This page narrows the focus to safeguards reported in clinical discussions, case literature, and regulatory caution around ibogaine.

Featured context

Start with the risk picture, not a promise

Ibogaine is a psychoactive substance, and its safety questions are inseparable from heart rhythm, co-occurring conditions, other substances, and the setting in which monitoring occurs. The FDA’s description of drug safety review is a useful reminder that safety assessment depends on evidence, context, and ongoing evaluation rather than a single reassuring claim.

Category 01

Cardiac screening is a central concern

Discussion of ibogaine safety regularly centers on cardiac rhythm. A baseline electrocardiogram, often called an ECG or EKG, is used in medical settings to examine the heart’s electrical activity. The standard description of electrocardiography explains why it is relevant when a substance may affect cardiac conduction.

Reviewing potassium and magnesium is also commonly included in risk-focused conversations. These electrolytes contribute to normal cardiac electrical function; low values can matter when QT-related risk is already under consideration. This is not a target range or a home-testing protocol: it is context for why laboratory review is treated as more than a paperwork step.

• ECG review: A current ECG may help identify rhythm or conduction concerns that require professional interpretation.
• Potassium and magnesium: These results are commonly considered alongside cardiac findings because electrolyte imbalance can add to rhythm vulnerability.
• Cardiac history: Prior arrhythmia, fainting, structural heart disease, or unexplained cardiac symptoms are not minor details in a risk discussion.

“A normal-looking single item does not cancel out other risks. The relevant question is how the whole picture is assessed.”

Category 02

Medication reconciliation and medical history need full attention

A careful medication reconciliation means reviewing prescribed medicines, over-the-counter products, supplements, and other substances rather than relying on an incomplete list. Particular attention is often given to medicines known to prolong the QT interval, as well as substances that may affect heart rhythm, seizure threshold, or metabolism. The CredibleMeds QT drug-risk resource is an established reference used to organize information about QT-prolonging medicines.

Medical history flags deserve the same seriousness. Cardiac disease, a seizure disorder, prior loss of consciousness, liver concerns, and other conditions can change the risk picture. A history of substance use or withdrawal is also relevant, but it does not erase the need to consider all other health factors.

Category 03

Hydration, nutrition, and observation are part of the safety context

Hydration and nutrition are not cosmetic wellness details. Poor intake, vomiting, diarrhea, or other conditions that affect fluids and electrolytes may change the clinical context of cardiac risk. The National Institute of Diabetes and Digestive and Kidney Diseases guidance on diarrhea notes dehydration and electrolyte imbalance as complications, illustrating why acute health changes should not be ignored.

Post-dose observation matters because risk is not limited to the first moment after taking a substance. Discussions of ibogaine safety commonly include a monitored window afterward, with the duration and intensity determined by the overall clinical picture. This is a reason to ask what monitoring is actually available—not a schedule for unsupervised use.

• Recent intake and illness: Food and fluid status, nausea, vomiting, diarrhea, and recent illness can be relevant to a fuller assessment.
• Appropriate observation: Monitoring plans should address the period after exposure rather than assuming risk ends immediately.
• Emergency readiness: A serious risk discussion includes what happens if concerning symptoms or a cardiac event occur.

Questions to hold onto

Use the checklist as a framework for better questions

It is reasonable to ask whether cardiac screening, laboratory review, a complete medication list, medical history flags, and a post-dose observation plan have been addressed. It is also reasonable to be wary of any setting that treats those questions as unnecessary or promises that risk can be removed.

Questions about how ibogaine is delivered are separate from questions about whether the surrounding safeguards are adequate. Our practical explainer on how ibogaine is administered can help readers distinguish route-of-administration information from the broader safety context.

For the site’s approach to evidence and plain-language boundaries, see the principles behind this independent resource. It is designed for people researching ibogaine, not as a replacement for medical or legal advice.